Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQJX0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL syringes. This delivery order, awarded on January 28, 2026, with an ultimate completion date of February 19, 2026, was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is authorized to fulfill this requirement under its single-award Indefinite Delivery Contract (SPE2DR) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply chain operations across the Department of Defense.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three optional 30-month renewal periods. This vehicle enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including biologics, specialty medications, and medical consumables to support military healthcare facilities worldwide. Xolair, a biologic immunosuppressant agent, aligns with DMS Pharmaceutical Group's established portfolio of specialty pharmaceutical products supplied to federal military medical systems, reflecting the company's critical role as a regional prime vendor contractor within the DLA's medical supply chain operations.
Quick answers
Who was awarded contract SPE2DR26FQJX0?
SPE2DR26FQJX0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQJX0 worth?
The government has obligated $15,792 on SPE2DR26FQJX0.
Is contract SPE2DR26FQJX0 an order under another contract?
Yes. SPE2DR26FQJX0 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJX0 competed?
The extent of competition for SPE2DR26FQJX0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award